Journal article
Chemoproteomic Profiling of a Carbon-Stabilized Gold(III) Macrocycle Reveals Cellular Engagement with HMOX2
Journal of medicinal chemistry, Vol.68(5), pp.5687-5698
03/13/2025
DOI: 10.1021/acs.jmedchem.4c02952
PMCID: PMC12206325
PMID: 39979117
Abstract
In this work, we discovered a novel organometallic gold(III) macrocycle, Au-Mac1, that demonstrates anticancer potency in a panel of triple-negative breast cancer cells (TNBC), and based on this complex, a biotinylated-Au-Mac1 probe was designed for target identification via chemoproteomics, which uncovered the engagement of HMOX2 of the heme-energy metabolism pathway. Using orthogonal chemical biology and molecular biology approaches, including immunoblotting, flow cytometry, and cellular thermal shift assays, it was confirmed that Au-Mac1 engages HMOX2 in cells. Downstream effects of Au-Mac1 on the depletion of mitochondrial membrane proteins and bioenergetics point to the potential role of HMOX2 in cancer. Importantly, Au-Mac1 inhibits in vivo tumor growth of metastatic breast tumor-bearing mice. We believe that this approach is clinically relevant in network-oriented drug discovery. To the best of our knowledge, Au-Mac1 is the first gold complex that targets HMOX2 to elicit an anticancer effect.
Details
- Title: Subtitle
- Chemoproteomic Profiling of a Carbon-Stabilized Gold(III) Macrocycle Reveals Cellular Engagement with HMOX2
- Creators
- Sailajah Gukathasan - University of KentuckyChibuzor Olelewe - University of KentuckyLibby Ratliff - University of KentuckyJong H Kim - University of KentuckyAlyson M Ackerman - University of KentuckyJ Robert McCorkle - University of KentuckySean Parkin - University of KentuckyGunnar F Kwakye - Oberlin CollegeJill M Kolesar - University of KentuckySamuel G Awuah - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Journal of medicinal chemistry, Vol.68(5), pp.5687-5698
- DOI
- 10.1021/acs.jmedchem.4c02952
- PMID
- 39979117
- PMCID
- PMC12206325
- NLM abbreviation
- J Med Chem
- ISSN
- 1520-4804
- eISSN
- 1520-4804
- Publisher
- AMER CHEMICAL SOC
- Grant note
- National Cancer Institute: R01CA258421-01 National Cancer Institute (NCI): NIH P20 GM130456 Center for Pharmaceutical Research and Innovation: CHE-997738 NSF: CHE-1625732 MRI program from NSFOffice of the Vice President of Research: P30 CA177558 NCI Center Core Support Grant
We are grateful for financial support from the National Cancer Institute (NCI) R01CA258421-01 (S.G.A.) and the UK Igniting research collaboration support (J.K. and S.G.A.). The authors also acknowledge the support of the Center for Pharmaceutical Research and Innovation (NIH P20 GM130456). We would like to thank the following facilities at the University of Kentucky who provided support in the completion of the experiments detailed in this manuscript. The UK NMR Center is supported by NSF (CHE-997738) and the UK X-ray facility is supported by the MRI program from NSF (CHE-1625732). For the flow cytometry experiments, we would like to thank the UK Flow Cytometry and Immune Function Core supported by the Office of the Vice President of Research, the Markey Cancer Center, and the NCI Center Core Support Grant (P30 CA177558). TNBC cells were gifted by Dr. Kathleen O'Connor.
- Language
- English
- Electronic publication date
- 02/20/2025
- Date published
- 03/13/2025
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Obstetrics and Gynecology
- Record Identifier
- 9984792363602771
Metrics
106 Record Views